ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Implications of liver injury in risk-stratification and management of patients with COVID-19

Shao, Jiaofang; Liang, Yuan; Li, Yan; Ding, Rong; Zhu, Mengyan; You, Wenhua; Wang, Ziyu; Huang, Bin; Wu, Min; Zhang, Tingting; Li, Kening; Wu, Wei; Wu, Lingxiang; Wang, Qianghu; Xia, Xinyi; Wang, Shukui; Lu, Ling南方医科大学; 南京大学; 中国医学科学院; 1
Hepatology International2021-2DOI: 10.1007/s12072-020-10123-0
14被引4阅读
引用收藏
分享

摘要

Background Infection with SARS-CoV-2 has been associated with liver dysfunction, aggravation of liver burden, and liver injury. This study aimed to assess the effects of liver injuries on the clinical outcomes of patients with COVID-19. Methods A total of 1520 patients with severe or critical COVID-19 from Huoshenshan Hospital, Wuhan, were enrolled. Chronic liver disease (CLD) was confirmed by consensus diagnostic criteria. Laboratory test results were compared between different groups. scRNA-seq data and bulk gene expression profiles were used to identify cell types associated with liver injury. Results A total of 10.98% of patients with severe or critical COVID-19 developed liver injury after admission that was associated with significantly higher rates of mortality (21.74%, p < 0.001) and intensive care unit admission (26.71%, p < 0.001). Pre-existing CLDs were not associated with a higher risk. However, fatty liver disease and cirrhosis were associated with higher risks, supported by evidences from single cell and bulk transcriptome analysis that showed more TMPRSS2(+) cells in these tissues. By generating a model, we were able to predict the risk and severity of liver injury during hospitalization. Conclusion We demonstrate that liver injury occurring during therapy as well as pre-existing CLDs like fatty liver disease and cirrhosis in patients with COVID-19 is significantly associated with the severity of disease and mortality, but the presence of other CLD is not associated. We provide a risk-score model that can predict whether patients with COVID-19 will develop liver injury or proceed to higher-risk stages during subsequent hospitalizations.

学科与关键词

关键词
Fatty liver diseaseViral hepatitisCirrhosisHospitalizationDisease progressionPrognosisICU admissionscRNA-seq analysisTMPRSS2Clinical prediction model
相关
加载中…
  • Liver injury in COVID-19: clinical features and treatment management
    Yu, Dongdong; Du, Qingru; Yan, Shengguang; Guo, Xu-Guang; He, Yehao; Zhu, Guodong; Zhao, Kewei; Ouyang, Shi*Virology Journal, 2021, 18(1): 121.被引 56
  • Gastrointestinal Infection and Liver Injury Are the Risk Factors for Coronavirus Disease 2019 Inpatients With Assisted Ventilation
    Lei, Ming; Qiu, Yue; Liu, Riguang; Huang, Jun; Huang, Xiaomei; Fan, Lixin; Hu, KaiYuan; Lin, Liu; Lei, Chunliang; He, Feng*; Qin, Shuguang*Liver Transplantation, 2021, 27(9): 1348-1354.被引 2
  • Quantitative assessment of fibrosis-4 score and adverse clinical outcomes in patients with COVID-19
    Tang, Kefu; Wang, Lu; Shen, Lu; He, Lin*; Wu, Xi*Science China Life Sciences, 2022, 65(12): 2560-2563.
查看全部 →

发表信息

论文状态
公开发表
期刊
Hepatology International
发表日期
2021-02
卷期
第 15 卷, 第 1 期
页码
202-212
DOI
10.1007/s12072-020-10123-0
语言
ENGLISH
期刊收录
NSL
期刊等级
2区
成果收录
SCIE
资助标注
National Natural Science Foundation of China [81971495, 81571564, 91442117, 81572893, 81972358, 91959113]; CAMS Innovation Fund for Medical Sciences [2019-I2M-5-035]; National Science Foundation of Jiangsu Province [BRA2017533, BK20191490, BE2016766]; 863 Young Scientists Special Fund [SS2015AA0209322]; Foundation of Jiangsu Collaborative Innovation Center of Biomedical Functional Materials, Key Foundation of Wuhan Huoshenshan Hospital [2020[18]]; Key Research& Development Program of Jiangsu Province [BE2017733, BE2018713]; Medical Innovation Project of Logistics Service [18JS005]; Basic Research Program of Jiangsu Province [BK20180036]

作者

  • S

    Shao, Jiaofang (第一作者)

    nanjing med univ

  • L

    Liang, Yuan

    nanjing med univ

查看全部 17 位作者收起作者
  • L

    Li, Yan

    nanjing med univ

  • D

    Ding, Rong

    nanjing med univ

  • Z

    Zhu, Mengyan

    nanjing med univ

  • Y

    You, Wenhua

    nanjing med univ

  • W

    Wang, Ziyu

    nanjing med univ

  • H

    Huang, Bin

    nanjing med univ

  • W

    Wu, Min

    nanjing med univ

  • Z

    Zhang, Tingting

    nanjing med univ

  • L

    Li, Kening

    nanjing med univ

  • W

    Wu, Wei

    nanjing med univ

  • W

    Wu, Lingxiang

    nanjing med univ

  • W

    Wang, Qianghu

    nanjing med univ

  • X

    Xia, Xinyi

  • W

    Wang, Shukui

    nanjing med univ

  • L

    Lu, Ling

    nanjing med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417